Clinical Efficacy of Etanercept hip joint Injection in the Treatment of Patients with Ankylosing Spondylitis

Objective: To evaluate the short-term efficacy of etanercept hip joint injection in the treatment of patients with ankylosing spondylitis.Methods: 50 cases with ankylosing spondylitis admitted in our hospital from 2001 to 2011 were injected into hip joint with etanercept 50 mg once a week for a treatment course of 4 weeks under the high-frequency ultrasound.The Bath Ankylosing Spondylitis Functional Index(BASFI),Bath Ankylosing Spondylitis Disease Activity Index(BASDAI),spinal pain VAS,(PGA)VAS,nocturnal spinal pain VAS,ESR,C-reactive protein(CRP),Harris and possible adverse reaction were observed at week 0,2,4,8 respectively.Results: Compared with the baseline,the observation items were all significantly improved after 2,4 and 8 weeks' treatment.At 2nd week,60%(n=30),26%(n=13) and 16%(n=8) of the patients achieved ASAS20,ASAS50 and ASAS70,respectively.At 8th week,the percentage of patients achieving the ASAS20/50/70 were 64%(n=38),42%(n=21),30%(n=15)respectively.The percentage of responders,above 70 of Harris was 90%,above 80 was 60%,and above 90 was 30%.1 patient had no improvement.And there were 4 patients below 70,but had recuding clinical signs.Conclusion: Etanercept was clinically effective and well tolerated in the treatment of AS patients,which could provide fast action,reduce clinical signs and improve range of motion as well as quality of life.